1Morrison L K, Harrison A, Krishnaswamy P, et al. Utility of a rapid natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea [J]. J Am Coll Cardiol, 2002, 39(2):202-209.
2Vasan R S, Benjamin E J, Larson M G, et al . Plasma brain natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfuntion: the Framingham heart study [J]. JAMA, 2002, 288(10) : 1252-1259.
3Bando M, Ishii Y, Sugiyama Y, et al . Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale [J]. Respir Med, 1999,93(7) :507-514.
5Abraham WT,Lowes BD,Ferguson DA,et al.Systemic hemodynamic,neurohormonal,and renal excretory effects of a steady-state infusion of human brain natriuretic peptide in patients with decompensated chronic heart failure.J Card Fail,1998,4:37-44.
6Mills RM,LeJemtel TH,Horton DP,et al.Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure:a randomized,double-blind,placebo-controlled clinical trial.Natrecor Study Group.J Am Coll Cardiol,1999,34:155-162.
7Colucci WS,Elkayam E,Horton DP,et al.Intravenous nesiritide,a natriuretic peptide,in the treatment of decompensated heart failure.N Engl J Med,2000,343:246-253.
8Kawakami R,Saito Y,Kishimoto I,et al.Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction.Circulation,2004,110:3306-3312.
9Keating GM,Goa KL.Nesiritide:a review of its use in acute decompensated heart failure.Drugs,2003,63:47-70.
10de Lemos JA,McGuire DK,Drazner MH.B-type natriuretic peptide in cardiovascular disease.Lancet,2003,362:316-322.
